DANVERS, Mass., Oct. 20 /PRNewswire-FirstCall/ -- Medwave, Inc. , the innovator in sensor-based, non-invasive blood pressure measuring solutions, announced today that a study titled “A Comparison of Radial Artery Blood Pressure Determination Between the Vasotrac Device and Invasive Arterial Blood Pressure Monitoring in Adolescents Undergoing Scoliosis Surgery” has been published in the October 2005 issue of Anesthesia & Analgesia.
The study was conducted at Children’s Hospital of Boston by Mary E. McCann, MD, David Hill, MBBS, Kristin C. Thomas, MS, RN, David Zurakowski, PhD, and Peter Laussen, MBBS, whose collective conclusion as stated within the journal was, “Our data suggest that the Vasotrac system correlates closely with intra-arterial blood pressure monitoring in anesthetized children under normotensive conditions in the prone position and during pharmacologic-induced hypotension.” Based on these results, it was also concluded that the Vasotrac is a reliable alternative to cuff and direct arterial blood pressure measurement during routine surgical cases.
In a previous report of children after congenital cardiac surgery, investigators at Children’s Hospital of Boston had demonstrated agreement between the Vasotrac measurements and those obtained from direct intra- arterial blood pressure monitoring, but that comparison was performed once patients were in stable condition after cardiac surgery.
This newly published study was performed to test the Vasotrac under wide blood pressure fluctuations, surgical blood loss, and in a different patient position. The Vasotrac monitor was evaluated against direct intra-arterial blood pressure measurement in adolescent children during scoliosis surgery. This study provides concrete data that the Vasotrac works in challenging patient populations and is a reliable alternative to cuff and direct arterial BP measurements during routine surgical cases.
Tim O’Malley, President and CEO of Medwave, Inc., stated, “Medwave’s strategy of supporting studies associated with our technology, specifically in difficult to monitor patient types or environments, has been very successful. We have had studies presented and published regarding the use of our technology with pediatric and obese patients, and in emergency medicine environments. All completed studies thus far have rendered positive results in which our technology has performed extremely well. Again, in this important new study that was conducted at Children’s Hospital in Boston, the results are very favorable, indicating further that our sensor-based blood pressure technology is the most innovative and advanced, non-invasive method of obtaining blood pressures in a multitude of settings and across a wide spectrum of patient types.”
Medwave, Inc. develops, manufactures, and distributes sensor-based non- invasive blood pressure solutions. Its Vasotrax(R) Hand Held Monitor, the Vasotrac(R) APM205A NIBP Monitor, the Vasotrac(R) APM205A Model DS, and the MJ23 OEM Module are new approaches to non-invasive blood pressure monitoring. Medwave’s latest addition, the Legato(TM) OEM Developers Kit, is designed to introduce the innovative Vasotrac(R) technology to OEM designers. Medwave has received the necessary regulatory clearances to market its technology in Europe, Asia, and the United States. Medwave’s technology is installed in over 500 hospitals and clinics worldwide. Medwave has received the Seal of Acceptance from the Alliance of Children’s Hospitals, as well as the Frost & Sullivan Market Engineering Award for Technology Innovation and the Frost & Sullivan Customer Value Enhancement Award. Medwave currently has supply and/or other agreements with Nihon Kohden, Zoll Medical Corporation, Analogic Corporation, and a global electronics company. Medwave trades on the NASDAQ small cap market under the symbol MDWV. For more information, visit http://www.medwave.com .
Statements made in this release that are stated as expectations, plans, anticipations, prospects or future estimates or which otherwise look forward in time are considered “forward-looking statements” and involve a variety of risks and uncertainties, known and unknown, which are likely to affect the actual results. The following factors, among others, as well as factors discussed in the Medwave’s filings with the SEC, have affected and, in the future, could affect Medwave’s actual results: resistance to the acceptance of new medical products, the market acceptance of the Vasotrac(R) system and other products of Medwave, hospital budgeting cycles, the possibility of adverse or negative results or commentary from clinical researchers or other users or evaluators of Medwave’s products, Medwave’s success in creating effective distribution channels for its products, Medwave’s ability to scale up its manufacturing process, and delays in product development or enhancement or regulatory approval. Consequently, no forward-looking statement can be guaranteed and actual results may vary materially. Medwave(R), Vasotrac(R), Vasotrax(R), and Legato(TM) are trademarks of Medwave, Inc.
Medwave, Inc.
CONTACT: Investors-Media, Jodie Chastain of Medwave, Inc.,+1-800-894-7601, jchastain@mdwv.com
Web site: http://www.medwave.com/
